Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825955 · ClinicalTrials.gov registry record · Phase 3
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
NCT00825955: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00825955 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 587 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00825955, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
Interventions
- OTHER Placebo
- DRUG Brivanib
- PROCEDURE Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2009-02-17 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 3 |
What the finished NCT00825955 record still lists
NCT00825955 is an interventional study that assigns participants to a tested intervention. The registered 587 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00825955 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00825955 about?
NCT00825955 is a clinical study titled "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment". The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
What is the current status of trial NCT00825955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2009-02-17. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT00825955?
The interventions under investigation include: Placebo (OTHER), Brivanib (DRUG), Best Supportive Care (PROCEDURE).
Who is sponsoring clinical trial NCT00825955?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00825955's enrollment target sits among peer trials
587 645th of 2000 higher than 1,354 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921603 · 588 participants · NA
POCUS-Guided Diuresis for Decompensated Heart Failure
- NCT06986954 · 588 participants
Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI